GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Leap Therapeutics is laying off half of its staff as the company narrows the focus of its lead cancer drug against the ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

An appeals court has opened another chapter in the long-running CRISPR patent saga. | An appeals court has opened another ...

The uncertainty around splitting up the business is only the latest in a series of strategic shake-ups at Galapagos in recent ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...